Athersys (NASDAQ:ATHX) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued on Tuesday, December 5th.
Several other equities research analysts also recently commented on the stock. Zacks Investment Research downgraded shares of Athersys from a “buy” rating to a “hold” rating in a research report on Thursday, August 31st. Maxim Group set a $12.00 price target on shares of Athersys and gave the stock a “buy” rating in a report on Thursday, November 16th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $7.17.
Athersys (NASDAQ:ATHX) traded down $0.03 on Tuesday, reaching $1.67. 268,980 shares of the company’s stock traded hands, compared to its average volume of 1,015,906. Athersys has a 12-month low of $1.02 and a 12-month high of $2.63.
In other Athersys news, insider William Lehmann, Jr. sold 15,000 shares of the business’s stock in a transaction dated Tuesday, September 19th. The shares were sold at an average price of $2.38, for a total value of $35,700.00. Following the transaction, the insider now directly owns 527,380 shares in the company, valued at $1,255,164.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 9.40% of the stock is owned by insiders.
Hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE lifted its stake in shares of Athersys by 17.2% during the 1st quarter. Bank of America Corp DE now owns 61,580 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 9,019 shares in the last quarter. SG Americas Securities LLC lifted its stake in shares of Athersys by 329.7% during the 2nd quarter. SG Americas Securities LLC now owns 73,434 shares of the biopharmaceutical company’s stock valued at $111,000 after buying an additional 56,345 shares in the last quarter. State of Wisconsin Investment Board purchased a new stake in shares of Athersys during the 2nd quarter valued at approximately $113,000. Blair William & Co. IL lifted its stake in shares of Athersys by 708.0% during the 2nd quarter. Blair William & Co. IL now owns 80,804 shares of the biopharmaceutical company’s stock valued at $122,000 after buying an additional 70,804 shares in the last quarter. Finally, Thompson Davis & CO. Inc. lifted its stake in shares of Athersys by 743.9% during the 3rd quarter. Thompson Davis & CO. Inc. now owns 64,303 shares of the biopharmaceutical company’s stock valued at $132,000 after buying an additional 56,683 shares in the last quarter. Institutional investors own 21.06% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2017/12/14/valuengine-downgrades-athersys-athx-to-sell.html.
Athersys Company Profile
Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.